Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-11-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2021.41 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849220290514518016 |
|---|---|
| author | Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello |
| author_facet | Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello |
| author_sort | Xiangqing Kong |
| collection | DOAJ |
| description | The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China. |
| format | Article |
| id | doaj-art-d6ea5947bafb402f8d01baee6e6bf6a7 |
| institution | Kabale University |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2021-11-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-d6ea5947bafb402f8d01baee6e6bf6a72024-12-14T16:03:07ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-11-011610.15420/ecr.2021.41Levosimendan in Europe and China: An Appraisal of Evidence and ContextXiangqing Kong0Xinqun Hu1Baotong Hua2Francesco Fedele3Dimitrios Farmakis4Piero Pollesello5First Affiliated Hospital, Nanjing Medical University, Nanjing, ChinaSecond Xiangya Hospital, Zhongnan University, Changsha, ChinaFirst Affiliated Hospital, Kunming Medical University, Kunming, ChinaDepartment of Clinical, Internal, Anaesthesiology and Cardiovascular Sciences, University ‘La Sapienza’, Rome, ItalyUniversity of Cyprus Medical School, Nicosia, CyprusCritical Care, Orion Pharma, Espoo, FinlandThe calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the profile of levosimendan in clinical trials conducted inside and outside China and grouped the findings under six headings: effects on haemodynamics, effects on natriuretic peptides, effect on symptoms of heart failure, renal effects, effect on survival, and safety profile. Their conclusions are that under each of these headings there are reasonable grounds to expect that the effects and clinical benefits established in trials and with wider clinical use in Europe and elsewhere will accrue also to Chinese patients. Therefore, the authors are confident that global experience with levosimendan provides a reliable guide to its optimal use and likely therapeutic effects in patients in China.https://www.ecrjournal.com/articleindex/ecr.2021.41 |
| spellingShingle | Xiangqing Kong Xinqun Hu Baotong Hua Francesco Fedele Dimitrios Farmakis Piero Pollesello Levosimendan in Europe and China: An Appraisal of Evidence and Context European Cardiology Review |
| title | Levosimendan in Europe and China: An Appraisal of Evidence and Context |
| title_full | Levosimendan in Europe and China: An Appraisal of Evidence and Context |
| title_fullStr | Levosimendan in Europe and China: An Appraisal of Evidence and Context |
| title_full_unstemmed | Levosimendan in Europe and China: An Appraisal of Evidence and Context |
| title_short | Levosimendan in Europe and China: An Appraisal of Evidence and Context |
| title_sort | levosimendan in europe and china an appraisal of evidence and context |
| url | https://www.ecrjournal.com/articleindex/ecr.2021.41 |
| work_keys_str_mv | AT xiangqingkong levosimendanineuropeandchinaanappraisalofevidenceandcontext AT xinqunhu levosimendanineuropeandchinaanappraisalofevidenceandcontext AT baotonghua levosimendanineuropeandchinaanappraisalofevidenceandcontext AT francescofedele levosimendanineuropeandchinaanappraisalofevidenceandcontext AT dimitriosfarmakis levosimendanineuropeandchinaanappraisalofevidenceandcontext AT pieropollesello levosimendanineuropeandchinaanappraisalofevidenceandcontext |